AI assistant
Traws Pharma, Inc. — Director's Dealing 2014
Feb 12, 2014
35199_dirs_2014-02-11_8c7865eb-baba-4064-824c-a9e452b466c9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Onconova Therapeutics, Inc. (ONTX)
CIK: 0001130598
Period of Report: 2013-02-07
Reporting Person: Kumar Ramesh (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-02-07 | Common Stock | M | 13543 | $6.00 | Acquired | 290043 | Direct |
| 2013-02-07 | Common Stock | S | 13543 | $15.02 | Disposed | 276500 | Direct |
| 2014-02-10 | Common Stock | M | 20000 | $6.00 | Acquired | 296500 | Direct |
| 2014-02-10 | Common Stock | S | 20000 | $15.11 | Disposed | 276500 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-02-07 | Stock Option (right to buy) | $6.00 | M | 13543 | Disposed | 2017-04-01 | Common Stock (13543) | Direct |
| 2014-02-10 | Stock Option (right to buy) | $6.00 | M | 20000 | Disposed | 2017-04-01 | Common Stock (20000) | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.16, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.40, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3: All the transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.
F4: 150,037 shares are held indirectly by the Ramesh Kumar 2012 Trust, of which the reporting person is a trustee.